BioNTech SE Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities
BioNTech SE (BNTX) reported Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities of -EUR 50.90 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities · last filed 2026-03-10
| Period end | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month as first filed |
|---|---|---|
| 2025-12-31 | -50.90M EUR 20-F · filed 2026-03-10 | |
| 2024-12-31 | -45.90M EUR 20-F · filed 2026-03-10 | |
| 2023-12-31 | -40.10M EUR 20-F · filed 2025-03-10 | |
| 2022-12-31 | -59.10M EUR 20-F · filed 2024-03-20 | |
| 2021-12-31 | -66.70M EUR 20-F · filed 2023-03-27 | |
| 2020-12-31 | 141.70M EUR 20-F/A · filed 2022-10-26 | 141.72M EUR 20-F · filed 2021-03-30 |
| 2019-12-31 | 7.94M EUR 20-F · filed 2021-03-30 | |
| 2018-12-31 | 3.47M EUR 20-F · filed 2020-03-31 |